Please try another search
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Name | Age | Since | Title |
---|---|---|---|
Ei Yamada | 72 | 2001 | CEO, President & Representative Director |
Katsunori Horikoshi | - | 2017 | Corporate Auditor |
Koichi Ando | - | 2021 | Corporate Auditor |
Naoyuki Ono | - | 2021 | Standing Corporate Auditor |
Naoya Sato | - | 2021 | Director of Corporate Development & Director |
Makoto Hara | 72 | 2018 | External Independent Director |
Norikazu Eiki | 75 | 2014 | External Independent Director |
Kimiko Murofushi | 76 | 2022 | External Independent Director |
Junichi Komamura | 73 | 2012 | External Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review